Manhattan Scientifics FCF per Share
Free Cash Flow per Share of Manhattan Scientifics (MHTX) as of Nov 11, 2026.
Get this data via API
Financial Data API
FCF per Share
-0.00USD
YoY
-45.56%
Last updated:
Free Cash Flow per Share of Manhattan Scientifics is 2023 -0.00 USD. Free Cash Flow per Share of Manhattan Scientifics was 2022 -0.00 USD. It decreases by -45.56% higher compared to the previous year.
The Manhattan Scientifics FCF per Share history
3 Years
10 Years
25 Years
Max
FCF per Share
Date
FCF per Share
Jan 1, 2016
-0.01 USD
Jan 1, 2017
-0.00 USD
Jan 1, 2018
-0.00 USD
Jan 1, 2019
-0.00 USD
Jan 1, 2020
-0.00 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
-0.00 USD
Jan 1, 2023
-0.00 USD
| YEAR | FCF per Share | YoY |
|---|---|---|
| -0.00USD | -45.56% | |
| -0.00USD | -17.10% | |
| -0.00USD | +7.40% | |
| -0.00USD | +22.17% | |
| -0.00USD | -55.36% | |
| -0.00USD | -14.14% | |
| -0.00USD | -82.52% | |
| -0.01USD | -245.63% | |
| 0.01USD | -216.23% | |
| -0.01USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Manhattan Scientifics Stock analysis
What does Manhattan Scientifics do? Manhattan Scientifics Inc is an innovative company that operates in the world of science and technology. The company was founded in 1994 by Marvin Maslow and is based in New York City. It primarily focuses on developing advanced technologies in the fields of materials science, biotechnology, and medical technology.
The business model of Manhattan Scientifics Inc is based on the discovery and development of new technologies, which are then licensed or sold. The company specializes in technology development and works closely with scientific institutions and researchers around the world. In the past, the company has collaborated closely with NASA and the Los Alamos National Laboratory, and has been able to bring several successful products to market.
The various divisions of Manhattan Scientifics Inc include nanotechnology, biotechnology, and medical technology. In the field of nanotechnology, the company has developed advanced technologies for the production of ultralight, highly strong materials. These materials are used in aerospace, construction, and other industries where lightweight and durable materials are needed.
The biotechnology division of Manhattan Scientifics Inc focuses on the development of novel therapies for cancer and other diseases. The company has successfully developed a new cancer therapy based on magnetic nanoparticles. These nanoparticles are introduced into the body and attach to cancer cells. They are then attracted and killed by an external magnetic field.
Medical technology is another important division of Manhattan Scientifics Inc. The company has developed advanced technologies for the production of medical devices that provide more precise surgeries and treatments. One of Manhattan Scientifics Inc's successful innovations is a device that can precisely target tumors with high-energy radiation to destroy them.
Manhattan Scientifics Inc has brought several successful products to market in the past. One example of such a product is the Greenshift Corporation System, which helps reduce emissions from airplanes. The company has also had successful collaborations with NASA on various projects, including the development of super-lightweight carbon fiber components.
Overall, Manhattan Scientifics Inc is an innovative company that specializes in the development of new technologies. The company has successfully worked in various fields, including nanotechnology, biotechnology, and medical technology. Its business model is based on the discovery and development of new technologies, which are then licensed or sold. Through its collaborations with scientific institutions and researchers around the world, the company has developed and brought several successful products to market. Manhattan Scientifics is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Manhattan Scientifics stock
On Eulerpool you can find the complete historical development of Free Cash Flow per Share Manhattan Scientifics since 2006 – with annual values, charts, and detailed analysis.
FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cash Flow — Manhattan Scientifics
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — Manhattan Scientifics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth